Guowei Fang

Dr. Guowei Fang has served as Senior Vice President, Global Head of Research and Early Development, since March, 2022. He is an accomplished scientist and pharmaceutical R&D leader who brings a wealth of experience in oncology and immunology to the role. Dr. Fang comes to Legend Biotech from Zymeworks Inc, where he served as SVP of Research and oversaw the development of novel platforms and a portfolio of multi-functional biologics and antibody drug conjugates. Prior to that, Dr. Fang led discovery and early development initiatives as Head of Discovery at Pharmacyclics, an AbbVie company. In that role, he built the Research, Discovery, Translation and Clinical Pharmacology organizations, delivered a broad pipeline of hematological assets and supported clinical development of IMBRUVICA®. Before joining Pharmacyclics, Dr. Fang worked at Genentech and AbbVie with a focus on oncology research and discovery. Prior to transitioning into pharmaceutical research and development, he was a faculty member at Stanford University leading cancer research initiatives.

Dr. Fang received his Doctor of Philosophy degree from University of Colorado under the mentorship of Dr. Thomas Cech and completed his postdoctoral training at Harvard Medical School under the mentorship of Dr. Marc Kirschner. He received his Bachelor of Science degree in biochemistry from Nanjing University. Dr. Fang has published over 60 manuscripts in cancer research and drug discovery and development, including primary publications in Science, Nature and Cell.